ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Vertex Partnerships Target Hepatitis C

by Michael McCoy
November 5, 2012 | APPEARED IN VOLUME 90, ISSUE 45

Vertex Pharmaceuticals is teaming up with Johnson & Johnson and GlaxoSmithKline in separate partnerships aimed at developing an all-oral hepatitis C treatment. Vertex and J&J’s Janssen Pharmaceuticals unit will conduct a Phase II study of a treatment combining Vertex’ polymerase inhibitor VX-135 and Janssen’s protease inhibitor simeprevir. Vertex and GSK will study a combination of VX-135 with GSK’s NS5A inhibitor GSK2336805. Last year, FDA approved Vertex’ Incivek protease inhibitor, but, like other hepatitis C drugs, it must be administered with unpleasant interferon injections.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment